We would love to hear your thoughts about our site and services, please take our survey here.
Company has forecast revenue mix and by 2026 we know that will be approximately 50% royalties.
We also know from the company the royalties are high margin (approx 90%).
So from your projections you can also get a good guide on profit. The company will be flooded in cash.
The current “unknown” is who will be the big DMS/OMS winners for the next phase of rfq for the 2027-2033 period.
I’m betting it’s SEE.
“ The original p1b design with it's straight dox comparison could have provided some data but that's all changed now. (After the famous whaler spork brawl)”
The dox arm was for comparison of efficacy though not to determine concentration of doxorubicin in tumors. Tumors are so heterogenous that that data is meaningless and reason the data doesn’t exist.
…..and at that stage they were still planning on the original 1b protocol emphasised by AS in the rns.
Cohort 6 has been a major breakthrough regarding efficacy to the point where protocol has changed dramatically to 2 weekly dosing.
I expect once the 2 weekly dosing efficacy is observed FDA breakthrough designation will occur and P2 will be conducted alongside approved ava6000.
“The BMW i Interaction EASE leverages Seeing Machines’ technology as a component of their innovative HMI (Human-Machine Interface) concept, visualized through a windshield projected Head-up Display (HUD).”
SEE been working with BMW for years.
Wrong.
“ Across the three companies, United Auto Workers union members voted a combined average of 97% in favor of a strike authorization, with votes still being tallied, the union said Friday. The vote does not mean a strike will be called, but that the union has the right to call one if they see fit.”
Mike this is from Cenkos….
Cash at year-end of US$36.8m was ahead of our expectations of US$25.9m with the difference relating to the remaining convertible loan note being drawdown from Magna (US$17.5m) offset by an increase in working capital (increased inventory and receivables) associated with the increasing aftermarket (Guardian) deliveries. The company expects this working capital position to unwind in H1/FY24E. We continue to see the company as fully funded to profitability in FY25E.
Cenkos - “Highly undervalued global technology market leader: With Seeing Machines exceeding our FY23E estimates and strong momentum across OEM and aftermarket divisions our confidence in strong growth towards profitability in FY25E increased. Furthermore, it looks like expectations are being better managed and the outlook for the company is looking increasingly exciting as a global technology leader in driver and operator monitoring systems. We continue to view Seeing Machines as highly undervalued compared to its market position in DMS, with rapid adoption in both OEM and aftermarket driven by regulation and awareness of the ability of DMS systems to save lives. We iterate our Buy recommendation and price target of 23.8p.”
I do and there are multiple mechanisms dependent on disease type not just one which you appear to be suggesting…..and many are not very well understood.
Alternative dosing regime/dosage level has the potential to negate these mechanisms……. Hence the need for escalation studies and MTD’s….. Simple.
Why would cells hit by dox released by ava6000 be more or less likely to develop resistance?
If they are all killed they can’t develop resistance 😉….. hence the need to find and MTD and expand dosage to the extreme.
Makes no difference to SEE. The tech will be put into all models, SEE will be paid at that point. What customers choose to pay for or not is between them and the OEM. The OEM’s have already committed to the technology being installed.
What we know is that SEE will be working with BMW, Mercedes, Ford, VW and others that have committed to buying $300m + of SEE dms which will be hitting the SEE accounts over the next few years at a 90% margin to SEE.
Worry about real world reviews all you like.
How can you invest in a company if you don’t even understand the technology or the testing of that technology?
“ As of writing this, Seeing Machines claims its driver monitoring systems have collectively travelled over 13 billion kilometres, amassing tons of real-world driving data.”
From an article published 15th August, 2023!
Short,
The only view that matters is that DMS is mandated into every new car in Europe in coming years which will be followed by the US and the rest of the world. OEM’s have also realised that they can utilise the cameras used in dms to monetise and modernise the incabin environment by understanding where the driver is looking which is driving features never thought possible previously.
Which company is the ultimate winner is still up for debate but SEE have positioned themselves well to take a significant share of the market.